Mar 22nd 2013 - Edison Investment Research today published a report on quickview entitled "Little Margin For Risk". In summary, the report says:
Mesoblast is an ASX-listed biotechnology company with a large R&D pipeline built on a proprietary stem cell technology. Mesoblast is developing allogenic cell therapies based on mesenchymal precursor cells in the areas of cardiovascular disease, diabetes, oncology, eye disease and orthopaedic diseases
Edison Investment Research is a leading international investment research company. It has won industry recognition, with awards both in the UK and internationally. The team of 95 includes over 60 analysts supported by a department of supervisory analysts, editors and assistants. Edison writes on more than 400 companies across every sector and works directly with corporates, fund managers, investment banks, brokers and other advisers. Edison’s research is read by institutional investors, alternative funds and wealth managers in more than 100 countries. Edison, founded in 2003, has offices in London, New York and Sydney and is authorised and regulated by the Financial Services Authority (www.fsa.gov.uk/register/firmBasicDetails.do?sid=181584). more »
